Chemotherapy-Induced Diarrhea (CID) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chemotherapy-Induced Diarrhea (CID) – Drugs In Development, 2024 report and make more profitable business decisions.
Chemotherapy-induced diarrhea (CID) is a common problem in patients with advanced cancer. The incidence of CID has been reported to be as high as 50-80% of treated patients, especially those treated with a 5-fluorouracil bolus or some combination therapies of irinotecan and fluoropyrimidines. Regardless of the molecular targeted approach of tyrosine kinase inhibitors and antibodies, diarrhea is a common side effect in up to 60% of patients, with up to 10% having severe diarrhea.
The Chemotherapy-Induced Diarrhea (CID) drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy-Induced Diarrhea (CID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy-Induced Diarrhea (CID) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chemotherapy-Induced Diarrhea (CID) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chemotherapy-Induced Diarrhea (CID) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chemotherapy-Induced Diarrhea (CID) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chemotherapy-Induced Diarrhea (CID) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
GP Pharm SAGuangzhou Zhiyi Biotechnology Co Ltd
Napo Pharmaceuticals Inc
OnQuality Pharmaceuticals LLC
Sanarentero LLC
Trobix Innovation Ltd
Usynova Pharmaceuticals Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chemotherapy-Induced Diarrhea (CID) reports